Once More, With Statistics: FDA Defends Division Productivity Differences
Executive Summary
Is it a problem that new drugs clear some review divisions faster than others? FDA analysis attributes differences to the proportion of applications qualifying for expedited review – a natural outgrowth of the priority placed on medical advances – not a management problem in need of a fix.
You may also be interested in...
Hematology, Neurology Star In Swan Song For The Office Of New Drugs’ Division Structure
Pink Sheet analysis of three years of novel US FDA approvals show the swiftest average time to approval in oncology, hematology, and antiviral divisions; neurology and hematology divisions contributed the most approvals.
Can US FDA's Talk Therapy Cure What Ails Mental Health R&D?
By reducing regulatory uncertainty, US FDA’s Breakthrough Therapy Designation is helping adventurous sponsors try new trial designs and new mechanism in the long-stagnant field of psychiatry drug development.
A Pathway, Not A Shortcut: 505(b)(2) NDAs Have Longer Reviews Than NMEs
US FDA's argument that its review resources favor novelty/medical advances could be buttressed by Tufts Center for the Study of Drug Development analysis of (less novel) approvals using the streamlined 505(b)(2) NDA pathway.